Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the main trial were approached to take part in the sub-st...
Κύριοι συγγραφείς: | Hale, J, Cohen, DR, Maughan, T, Stephens, R |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2002
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
ανά: Maughan, T, κ.ά.
Έκδοση: (2002) -
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
ανά: Moe, M, κ.ά.
Έκδοση: (2008) -
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
ανά: Maughan, T, κ.ά.
Έκδοση: (2010) -
A cost comparison of biologic treatment regimens for metastatic colorectal cancer in Italy
ανά: Sergio Iannazzo, κ.ά.
Έκδοση: (2017-10-01) -
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
ανά: Adriana Camargo Carvalho, κ.ά.
Έκδοση: (2017-01-01)